HIGHBuilt-in & outside partyPipeline
lead product candidate [225Ac]Ac-AKY-1189
“10-K Item 1A: 'Our business is highly dependent on our lead product candidate, [225Ac]Ac-AKY-1189, for the treatment of Nectin-4 expressing tumors.'”
AKTS · Concentration risk · 10-K extracted
Aktis Oncology (AKTS) concentration risks
Updated
The most significant concentration Aktis Oncology discloses is lead product candidate [225Ac]Ac-AKY-1189, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Aktis Oncology’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Aktis Oncology's concentration profile is dominated by a single, high-share exposure: the company is highly dependent on its lead product candidate, [225Ac]Ac-AKY-1189, for the treatment of Nectin-4 expressing tumors. This is a pipeline concentration with mixed character — part structural (a clinical-stage biotech necessarily concentrates resources on its most advanced asset) and part dependency (near-term value is tied to one program's clinical and regulatory outcomes rather than a diversified portfolio). Unlike a customer or geographic concentration, this exposure cannot be hedged by contract renegotiation or geographic diversification; it moves with trial readouts, regulatory decisions, and manufacturing execution for that specific candidate. Because no other concentration claims are disclosed here, the entire near-term investment thesis effectively rests on this one program's progress. A positive data readout or regulatory milestone would be the primary catalyst that could shift the verdict, while a clinical setback or delay would have an outsized effect on the stock precisely because there is no offsetting diversification elsewhere in the disclosed risk profile. Investors should treat this as the single dominant variable in the name.
For the engine’s reasoning on AKTS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| AKTS● | Aktis Oncology, Inc. | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.